Evidence map›Paper›PMID 26624524›Full record

ArticleJournal of psychiatry & neuroscience : JPN2016

Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.

Carolina Alquézar, Ana de la Encarnación, Fermín Moreno, Adolfo López de Munain, Ángeles Martín-Requero

Open access · bronzeAbstract read
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Complexity of progranulin mechanisms of action in mesothelioma.Journal of experimental & clinical cancer research : CR · 2022
    Article
  10. Article
  11. The value ofAnnals of translational medicine · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Progranulin Regulates Inflammation and Tumor.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Carolina AlquézarFrom the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
Ana de la EncarnaciónFrom the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
Fermín MorenoFrom the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
Adolfo López de MunainFrom the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
Ángeles Martín-RequeroFrom the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
University of the Basque Country · ESBiogipuzkoa Health Research Institute · ESCentre for Biomedical Network Research on Rare Diseases · ESInstituto de Investigación de Enfermedades Raras · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLoss-of-function progranulin gene (GRN) mutations have been identified as the major cause of frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein 43 (TDP-43) pathology (frontotemporal lobar degeneration [FTLD]-TDP); however, little is known about the association between progranulin (PGRN) deficiency and neuronal loss in individuals with FTLD-TDP. Previously we reported enhanced proliferative activity associated with the activation of WNT5A/CDK6/pRb signalling in PGRN-deficient cells. The objective of this work was to elucidate the association between PGRN deficiency, WNT5A signalling and cell proliferation in immortalized lymphoblasts from carriers of the c.709-1G > A GRN mutation (asymptomatic and FTLD-TDP).

methodsWe assessed cell proliferation in carriers of the c.709-1G > A GRN gene mutation and controls without GRN mutation and without sign of neurologic degeneration by cell counting or using an MTT assay. We used a luciferase assay to measure the nuclear factor-κ (NF-κ) activity. We evaluated messenger RNA levels using quantitative real-time polymerase chain reaction and protein levels by immunoblotting. Co-immunoprecipitation was used to analyze the interaction between PGRN and its receptors.

resultsWe enrolled 19 carriers of the GRN gene mutation and 10 controls in this study. The PGRN-deficient cells showed increased expression of WNT5A due to NF-κB signalling overactivation. We observed a competition between PGRN and tumour necrosis factor-α (TNF-α) for binding both TNF receptors (TNFR) I and II. Blocking NF-κB signalling using wedelolactone or specific antibodies against TNFRs inhibited WNT5A overexpression and proliferation of PGRN-deficient cells. Conversely, the activation of NF-κB signalling by TNF-α increased WNT5A-dependent proliferation of control cells. LIMITATIONS: All cell lines were derived from individuals harboring the same splicing GRN mutation. Nevertheless, most of the known GRN mutations lead to haploinsufficiency of the protein.

conclusionOur results revealed an important role of NF-κB signalling in PGRN-associated FTLD-TDP and confirm that PGRN can bind to TNF-α receptors regulating the expression of WNT5A, suggesting novel targets for treatment of FTLD-TDP linked to GRN mutations.

Indexed as

AdultAgedCell ProliferationCells, CulturedCoumarinsCyclin-Dependent Kinase 6FemaleFrontotemporal DementiaHeterozygoteHumansIntercellular Signaling Peptides and ProteinsLoss of Function MutationLymphocytesMaleMiddle AgedNeuroblastomaCDK6 protein, humanCoumarinsCyclin-Dependent Kinase 6GRN protein, humanIntercellular Signaling Peptides and ProteinsNF-kappa BProgranulinsProtein Kinase InhibitorsReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IRNA, MessengerTumor Necrosis Factor-alphawedelolactoneWnt-5a ProteinWNT5A protein, human

Identifiers

PMID26624524
PMCPMC4915932
OpenAlexW2410639191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.